What question did this study set out to answer?

To examine the prevalence and implications of biologic dose escalation in patients with inflammatory bowel disease.

March 2, 2026

Biologic dose escalation in inflammatory bowel disease in the United States

Key Points

To examine the prevalence and implications of biologic dose escalation in patients with inflammatory bowel disease.
Analyzed patient data on biologic therapy use
Assessed dose escalation frequency
Evaluated associated healthcare costs
One-third of patients escalated their biologic dose
Significant increase in disease-related healthcare costs
Identified challenges in managing long-term biologic therapy in IBD

Abstract

Nearly one-third of patients with IBD in this study escalated their biologic dose, which significantly increased their disease-related health care costs. These results demonstrate current challenges in long-term biologic therapy in IBD and highlight the ongoing need for further research into biologic management strategies to optimize IBD patient care and long-term outcomes, while containing costs.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Casey Chapman

Aisha Vadhariya

Eli Lilly (United States)

Nicholas Bires

Eli Lilly (United States)

Journals

Journal of Managed Care & Specialty Pharmacy

Actions

Institutions

Eli Lilly (United States)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Biologic dose escalation in inflammatory bowel disease in the United States

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study